Quote | Bausch Health Companies Inc. (TSXC:BHC:CC)
Last: | $5.88 |
---|---|
Change Percent: | -0.34% |
Open: | $5.9 |
Close: | $5.90 |
High: | $6.15 |
Low: | $5.7 |
Volume: | 1,784,767 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Bausch Health Companies Inc. (TSXC:BHC:CC)
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with t...
2024-05-07 09:15:00 ET Summary Bausch Health Companies stock experienced a significant drop after posting its first-quarter results, missing expectations by 13 cents. The company's debt maturity profile raises concerns for investors, with a large amount of debt maturing in 2025 an...
Message Board Posts | Bausch Health Companies Inc. (TSXC:BHC:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC:CC Stock Symbol:
TSXC Market:
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with t...
Kelt Exploration Ltd. (KEL:CA) is expected to report $0.07 for Q1 2024 Electrovaya Inc. (ELVA:CA) is expected to report $0.03 for Q2 2024 Western Copper and Gold Corporation (WRN:CA) is expected to report for Q1 2024 Galiano Gold Inc. (GAU:CA) is expected to report $-0.03 for Q1 2024 ...
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic 1 basis Year-over-year revenue growth in all segments on both a Reported and Organic 1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable t...